Chronic Myeloid Leukemia (CML) Precision TKI Therapy & Specialist Access
CML is a myeloproliferative neoplasm defined by the BCR-ABL1 fusion gene (Philadelphia chromosome), making it the first cancer routinely treated with a molecularly targeted oral therapy. TKI treatment has transformed CML from a life-threatening leukaemia into a chronically manageable — and in many patients treatment-free — condition. CancerFax connects patients with specialist haematologists for optimal TKI selection, mutation testing, and advanced care access.
- BCR-ABL1 Driven — Highly Targetable
- 5 Generations of TKIs Available
- Treatment-Free Remission Achievable
- Expert TKI Selection & Resistance Testing
- Annual Incidence (Global)
- ~1–2 per 100,000
- Defining Alteration
- BCR-ABL1 (Philadelphia Chromosome)
- Chronic Phase at Diagnosis
- ~90% of patients
- TKIs Available
- Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, Asciminib
- Treatment-Free Remission
- Achievable in ~40–50% of deep MR4.5 patients
Condition Overview
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative neoplasm arising in a pluripotent haematopoietic stem cell and defined by the presence of the BCR-ABL1 fusion gene — the molecular consequence of the Philadelphia chromosome translocation t(9;22)(q34;q11). The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase that drives uncontrolled myeloid cell proliferation. CML accounts for approximately 15–20% of adult leukaemias and has an annual incidence of 1–2 per 100,000 globally.
The discovery that BCR-ABL1 kinase drives CML led directly to the development of imatinib (Gleevec/Glivec) — the first targeted cancer kinase inhibitor — which transformed CML management after its approval in 2001. Five generations of BCR-ABL1 tyrosine kinase inhibitors (TKIs) are now available: imatinib, dasatinib and nilotinib (second generation), bosutinib (second generation), ponatinib (third generation, pan-BCR-ABL1 inhibitor active against T315I), and asciminib (STAMP inhibitor — first-in-class myristoyl pocket binder, third generation). This successive development has addressed resistance mutations, improved depth of molecular response, and enabled treatment-free remission (TFR) in an increasing proportion of patients.
CML progresses through three phases: chronic phase (CP-CML, ~90% at diagnosis, characterised by myeloid expansion without blast excess), accelerated phase (AP-CML, blast increase 10–19% with additional cytogenetic changes), and blast crisis (BC-CML, ≥20% blasts with myeloid or lymphoid phenotype, behaving like acute leukaemia). The treatment goal in chronic phase CML is deep molecular remission (MR4 or MR4.5 — BCR-ABL1 transcript below 0.01% or 0.0032% on the International Scale) and ultimately treatment-free remission (TFR) for patients who sustain deep remission. Blast crisis requires intensive treatment including TKI plus acute leukaemia induction chemotherapy.
Types and Disease Phases
CML is classified by disease phase at presentation, which fundamentally determines prognosis and treatment approach. The vast majority of patients are diagnosed in chronic phase on routine blood count. Phase progression reflects clonal evolution and acquisition of additional oncogenic alterations beyond BCR-ABL1.
Symptoms and Signs
CML in chronic phase is frequently diagnosed incidentally on a routine blood count showing leucocytosis, before significant symptoms develop. When symptoms are present, they reflect the myeloid expansion, splenomegaly, and anaemia of the disease. Phase progression to accelerated or blast crisis produces rapidly worsening symptoms.
Causes and Risk Factors
CML arises from a somatic chromosomal translocation — the Philadelphia chromosome — in a single haematopoietic stem cell. The biological trigger for this translocation in most patients is unknown. A small number of established risk factors have been identified, primarily related to radiation exposure.
Diagnosis and Investigations
CML diagnosis is established by demonstrating BCR-ABL1 fusion either by cytogenetics (Philadelphia chromosome on karyotype), FISH (BCR-ABL1 fusion signal), or quantitative RT-PCR (BCR-ABL1 transcript). Once confirmed, baseline molecular quantification and disease phase assessment are completed before TKI selection.
Staging and Risk Stratification
CML is stratified by disease phase (chronic, accelerated, blast crisis) and by clinical risk score at diagnosis (Sokal, EUTOS, ELTS in chronic phase). During treatment, molecular response milestones define treatment success and guide TKI adjustment decisions. ELN (European LeukemiaNet) 2020 response milestones are the international standard.
Standard Treatment
TKI therapy is the cornerstone of CML treatment across all phases. The choice of frontline TKI and subsequent decisions are guided by disease phase, risk score, comorbidities, tolerability, and — at failure — mutation profile. Treatment-free remission (TFR) is a defined clinical goal for patients achieving sustained MR4.5 on optimal TKI therapy.
Advanced and Emerging Therapies
The CML treatment landscape continues to evolve with asciminib's emergence as a highly active STAMP inhibitor with a unique binding mechanism, and with novel combination approaches seeking to improve TFR rates. CancerFax supports access to specialist CML centres and clinical trials globally.
STAMP Inhibitor (Third-Generation TKI)
Asciminib (Scemblix) — BCR-ABL1 Myristoyl Pocket Binder
Asciminib targets the BCR-ABL1 myristoyl pocket (distinct from the ATP-binding site targeted by all prior TKIs) — a mechanism that retains activity against many ATP-binding site mutations including T315I (at 200 mg BID). Approved (2021) for CP-CML/AP-CML after ≥2 prior TKIs and at 200 mg BID specifically for T315I-positive disease. The ASC4FIRST trial demonstrates superiority over imatinib and second-generation TKIs as frontline therapy in CP-CML, establishing asciminib as a frontline option. Combination with other TKIs exploits the distinct binding site to overcome compound mutations.
Third-Generation TKI
Ponatinib (Iclusig) — Pan-BCR-ABL1 Inhibitor Including T315I
Ponatinib is the only approved agent (prior to asciminib 200 mg BID) with activity against T315I-mutant BCR-ABL1. FDA-approved for CP/AP/BC-CML with T315I or for whom no other TKI is indicated. The OPTIC trial established a response-adapted dosing strategy (45 mg/day reducing to 15 mg/day on achieving BCR-ABL1 IS ≤1%) to improve the cardiovascular risk profile. Arterial occlusive events remain the key safety concern; comprehensive CV risk management is mandatory.
Allogeneic Stem Cell Transplantation
Allo-SCT — Blast Crisis or Multi-Resistant CML
Allo-SCT remains the only curative option for blast crisis CML and for young patients with multiple TKI-resistant CP/AP-CML achieving remission. The graft-versus-leukaemia effect provides sustained disease control independent of BCR-ABL1 status. Indications have narrowed substantially in the TKI era but allo-SCT retains a critical role in blast crisis and pan-resistant cases. Donor searching should begin early in blast crisis management.
TKI + Venetoclax Combination
Dasatinib + Venetoclax — Blast Crisis CML
BCL-2 dependency in CML blast crisis cells has been exploited in investigational combinations of TKIs with venetoclax. Early-phase data from multiple academic centres show activity in CML-BC (both myeloid and lymphoid). Particularly relevant for myeloid blast crisis where AML-type resistance to standard induction is anticipated. Under investigation at specialist CML centres.
Frontline Asciminib Combinations
Asciminib + Dasatinib/Nilotinib — TFR Optimisation
Combining asciminib (myristoyl pocket) with an ATP-site TKI exploits dual-mechanism inhibition to achieve very deep molecular responses and potentially higher TFR rates. Early-phase combination trials (asciminib + nilotinib or dasatinib) are demonstrating high MR4.5 rates in both newly diagnosed and pretreated CP-CML patients. Future standard of care in high-risk or TFR-seeking patients.
China Access — Specialist CML Programmes
TKI Access and CML Trials in China
Chinese haematology centres — including Ruijin Hospital Shanghai (National Research Centre for Haematological Diseases), Peking Union Medical College Hospital, and Institute of Haematology Tianjin — have among the highest CML patient volumes globally and active TKI and stem cell transplant programmes. Zanubrutinib, olverembatinib (third-generation TKI developed in China, approved by NMPA for T315I-mutant CML), and asciminib are available or in trials in China. CancerFax supports patients in accessing these programmes.
Biomarkers and Precision Medicine
CML is the paradigm precision oncology disease — a single molecular driver (BCR-ABL1) defines the diagnosis, a single test (quantitative PCR) monitors treatment response, and resistance mutations in BCR-ABL1 directly guide TKI selection. Biomarker monitoring is continuous throughout treatment.
When to Seek a Second Opinion
Despite the availability of highly effective TKIs, CML management requires specialist expertise in molecular monitoring, resistance mutation interpretation, and TFR guidance. Several specific situations in CML warrant specialist second opinion.
Clinical Trials and Research in CML
Prognosis and Outcomes
CML in chronic phase treated with TKI therapy has an outstanding prognosis — the life expectancy of CP-CML patients achieving optimal molecular response approaches that of the age-matched general population. Blast crisis remains challenging with a much more guarded outlook. The era of TKI therapy has transformed CML from one of the most feared leukaemias into a chronically manageable condition for most patients.
Supportive Care
Supportive care in CML primarily addresses TKI side effect management, adherence support, and monitoring for cardiovascular and other long-term toxicities of chronic TKI use. TFR-related anxiety management is an increasingly important supportive care consideration.
How CancerFax Helps You Explore Treatment Options
CancerFax supports CML patients by reviewing BCR-ABL1 PCR results and kinase domain mutation panels, facilitating specialist haematology second opinions on TKI selection and treatment failure management, identifying access to ponatinib, asciminib, and olverembatinib for T315I-mutant or multi-resistant disease, and coordinating consultations with leading CML programmes in India, China, and internationally.
Get a free case reviewFrequently Asked Questions
Chronic Myeloid Leukemia (CML) is a blood cancer in which a chromosomal translocation — the Philadelphia chromosome, t(9;22) — fuses the BCR gene (chromosome 22) with the ABL1 gene (chromosome 9), creating the BCR-ABL1 fusion oncogene. The BCR-ABL1 protein is a permanently switched-on tyrosine kinase that drives the uncontrolled proliferation of myeloid blood cells. This chromosomal change is acquired (not inherited) — it occurs in a single stem cell as a somatic event, the trigger for which is usually unknown (ionising radiation is an established risk factor). CML is the paradigm precision oncology disease — its single molecular driver (BCR-ABL1) is the direct target of TKI therapies that have transformed the outlook of this disease.
Tyrosine Kinase Inhibitors (TKIs) are oral targeted drugs that block the BCR-ABL1 protein's kinase activity — the switch that drives CML cell proliferation. By blocking BCR-ABL1, TKIs prevent CML cells from receiving the survival and growth signals they depend on, causing them to stop multiplying and eventually die. Six TKIs are approved for CML: imatinib (first-generation), dasatinib, nilotinib, bosutinib (all second-generation), ponatinib (third-generation, active against T315I mutation), and asciminib (STAMP inhibitor targeting a different BCR-ABL1 binding site from all others). Each subsequent generation was developed to overcome resistance mutations and achieve deeper molecular responses.
BCR-ABL1 IS PCR is a blood test that measures the level of BCR-ABL1 leukaemia gene transcript remaining in the body, expressed as a percentage on the International Scale (IS). It is performed every 3 months during the first 2 years of TKI therapy. The IS allows standardised comparison between laboratories worldwide. Treatment milestones define adequate response: BCR-ABL1 IS ≤10% at 3 months (early molecular response), ≤1% at 6 months, ≤0.1% (major molecular response / MMR) at 12 months. Deeper responses (MR4 ≤0.01%, MR4.5 ≤0.0032%) enable consideration of treatment-free remission. A rising BCR-ABL1 IS above the previously achieved level on two consecutive tests is a treatment failure signal requiring urgent assessment.
Treatment-free remission (TFR) means stopping TKI therapy while maintaining molecular remission — essentially living without leukaemia treatment and without disease detectable in the blood. It is achievable in approximately 40–50% of eligible patients. The criteria for attempting TFR (per ELN 2020 guidelines) are: at least 5 years of any TKI, stable deep molecular response (MR4 or MR4.5 — BCR-ABL1 IS ≤0.01% or lower) for at least 2 years, and access to monthly BCR-ABL1 IS monitoring for the first year after stopping. If the BCR-ABL1 rises above the major molecular response threshold, TKI is restarted promptly — re-achieving remission in virtually all patients. TFR should only be attempted under the supervision of a specialist CML haematologist.
The T315I mutation is a single amino acid substitution in the BCR-ABL1 kinase domain (threonine to isoleucine at position 315 — the 'gatekeeper' residue) that makes BCR-ABL1 resistant to binding by all first- and second-generation TKIs (imatinib, dasatinib, nilotinib, bosutinib). It is detected in approximately 15–20% of patients with TKI resistance. Its importance is that it immediately eliminates all standard TKI options except ponatinib (approved at 45 mg/day with response-adapted dose reduction) and asciminib 200 mg BID (approved specifically for T315I). Detection of T315I requires an immediate TKI switch to one of these agents. T315I testing is part of the kinase domain mutation panel performed at any CML treatment failure.
Blast crisis (BC-CML) is the most advanced and most serious phase of CML, defined by the presence of ≥20% immature blast cells in the blood or bone marrow. At this point, CML has transformed into an acute leukaemia — either myeloid (behaving like AML) or lymphoid (behaving like ALL). Unlike chronic phase CML, blast crisis cannot be controlled by TKI alone; it requires TKI combined with intensive acute leukaemia induction chemotherapy (AML-type or ALL-type depending on blast phenotype). Allogeneic stem cell transplantation in first complete haematological response is the goal in eligible patients, as it is the only approach with established long-term disease control in blast crisis.
Yes — six TKIs are currently approved for CML, each with different efficacy, resistance profiles, and toxicity characteristics. The choice depends on several factors: your disease phase (chronic versus advanced), your clinical risk score at diagnosis (Sokal or ELTS), the presence of BCR-ABL1 resistance mutations (particularly T315I), your cardiovascular health (nilotinib and ponatinib carry cardiovascular risks; dasatinib carries pleural effusion and pulmonary hypertension risk), your other health conditions, and your treatment goals (deep remission for TFR versus tolerability). A specialist CML haematologist integrates all these factors to recommend the most appropriate TKI and switch strategy if needed.
CML can occur in children and adolescents, accounting for approximately 2–3% of all CML diagnoses. The disease biology is identical to adult CML — the Philadelphia chromosome and BCR-ABL1 fusion are the defining abnormalities. Treatment with TKIs follows adult principles, though paediatric dosing and long-term toxicity monitoring (growth, fertility, cardiovascular effects of lifelong TKI) require specialist paediatric haematology-oncology management. Imatinib and dasatinib have paediatric approvals for CML. The long-term goal of TFR is particularly important in young patients to minimise lifelong TKI exposure and its late effects.
Yes. CancerFax supports CML patients by reviewing BCR-ABL1 PCR results and kinase domain mutation reports, facilitating specialist haematology second opinions on TKI selection, resistance management, and TFR eligibility, identifying access to ponatinib, asciminib, and olverembatinib for T315I-mutant or multi-resistant disease, and coordinating consultations with leading CML programmes in India, China, and internationally. Please share your BCR-ABL1 PCR results, mutation panel, and treatment history with CancerFax via our portal or contact our team to begin.
Managing CML? CancerFax Connects You With Expert TKI and Specialist Care.
From BCR-ABL1 monitoring and TKI selection to T315I resistance management, TFR eligibility, and blast crisis treatment, CancerFax helps CML patients access specialist haematology expertise and advanced therapy globally.